XERS has had a standout week — up 16.6% to $8.73 — yet the stock sits well below where its most bullish analyst believes it belongs, and options traders are quietly turning more cautious even as the rally runs.
The clearest acceleration in sentiment came from the analyst community. Leerink Partners raised its price target from $12 to $16 on September 10, maintaining an Outperform rating. That followed Barclays lifting its target from $9 to $12 in August. Both moves point the same direction: the Street is chasing the stock higher after a strong operational stretch. The mean price target across coverage now rests at $12.33, implying the stock remains roughly 41% below the consensus view at current levels — though that average is dragged down by HC Wainwright's $10 target, which hasn't moved since early March. Oppenheimer holds the most aggressive view at $18. The bull case rests on Recorlev revenues more than doubling year-over-year to $22.6 million in the most recent quarter reported, new prescription starts growing 123%, and forward earnings momentum ranking in the 90th percentile of the ORTEX universe. Bears counter with generic competition risk, ongoing net losses, and revenue guidance for 2025 that offered only a modest beat of prior estimates.
Short interest tells a muted story here, and it doesn't deserve to lead. At roughly 5% of the free float — about 8.25 million shares — the short position is present but not extreme, and it has drifted lower over the past month, falling around 7.5% from August levels. Cost to borrow has ticked up 21% on the week to 0.52%, which sounds notable until you look at the absolute level: that's still well under 1%, firmly in the "easy borrow" category. Borrow availability is essentially unconstrained — the lending pool holds nearly 100 million shares available against a short position of 8.25 million, keeping availability at multiples of outstanding short interest. Nothing in the lending market is restricting short sellers or threatening a technical squeeze. Options, however, tell a slightly different story. The put/call ratio has climbed to 0.21, nearly two standard deviations above its 20-day average of 0.16. That's not extreme in absolute terms — the 52-week high is 0.50 — but the direction is clear: some participants are buying more downside protection into the rally than they were two weeks ago. Positioning looks moderately cautious rather than aggressively bearish.
The institutional register has been quietly building. BlackRock increased its stake to 14.5 million shares, representing nearly 8% of the company, as of August 31. Vanguard Capital Management separately crossed the 5% threshold in July and filed a Schedule 13G. No 13D activist filer is on the register — the 13D/G activity here is passive accumulation, not agitation. Worth noting: The Vanguard Group's earlier filing now shows a zero stake after reporting 6.74% previously, suggesting the entity restructured holdings across its various managed vehicles. The insider picture is less encouraging from a conviction standpoint, but the framing matters. Multiple insiders sold shares on September 1 — Hecht, McCulloch, and Pieper — but every transaction was executed under a pre-arranged 10b5-1 plan. These are scheduled, programmatic sales, not discretionary exits. Net insider selling over the past 90 days totals around $2.25 million across roughly 291,000 shares, all under plan. The absence of any open-market buying is a mild negative signal, but it would be wrong to read the plan-governed sales as a vote of no-confidence.
The next earnings print is scheduled for November 6. The most recent result — from August 6 — produced a modest 1-day decline of about 2.2%, followed by a 5-day recovery of 2.7%. That pattern suggests the stock tends to absorb results without dramatic directional moves, at least recently. Peers had a good week too: AMRX gained 17% and COLL added 4.3%, suggesting the rally in XERS had some sector tailwind rather than being purely idiosyncratic.
With the November earnings date in view, the key question is whether the top-line momentum in Recorlev and Gvoke holds — and whether the Street's target-raise cycle has more room to run or has already pulled forward the good news into the price.
See the live data behind this article on ORTEX.
Open XERS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
